A prospective cohort study to identify biomarkers predicting the regression of grade 2 Cervical Intraepithelial Neoplasia. Study protocol

Objective: The detection and treatment of high-grade cervical lesions prevent the development of invasive cervical cancer. Excisional procedures can pose a risk for subsequent pregnancies, thus conserva-tivemanagement of Cervical Intraepithelial Neoplasia grade 2 (CIN2) lesions should be adopted in young women. The aim of our study is to evaluate the ability of viral and cellular biomarkers in predicting regression/progression of CIN2. Methods: Women aged 25 to 45 years, participating to population-based organised cervical cancer screening programmes in the Veneto Region (Italy), diagnosed with a CIN2 lesion and fitting predefined inclusion/exclusion criteria, are invited to take part in a multicentre observational longitudinal cohort study with a follow-up of 24 months. Upon signing an informed consent, women are enrolled in the study and cervical cell samples collected. Treatment is delayed and subsequently performed in the case of lesion progression, or persistence for >12 months. HPV genotyping, p16INK4A/ki67 expression and methylation status for L1 viral sequences and FAM19A4/miR124-2 cellular genes are determined at baseline and during follow-up, and evaluated in relation to the clinical outcome. Results: The study, registered on ClinicalTrials.gov (ID: NCT04687267), is currently ongoing. Enrolment of women aged 25–45 years started in 2019, and will continue up to the end of 2021. Discussion: Since February 2020, the Veneto Region has been hit by the COVID-19 pandemic. The enrolment of women in the study was interrupted during an initial two-month lockdown, and slowed down during the subsequent months. The 12-month extension of the study period will partially counterbalance this delay.

Cervical screening; CIN2; Conservative management; Regression; Progression; Biomarkers; HPV genotyping; Methylation

[1] Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al. Human papillomavirus and related diseases in the world. 2019. Available at: hpvcentre.net/statistics/reports/XWX.pdf (Accessed: 9 April 2021).

[2] Serraino D, Gini A, Taborelli M, Ronco G, Giorgi Rossi P, Zappa M, et al. Changes in cervical cancer incidence following the introduction of organized screening in Italy. Preventive Medicine. 2015; 75: 56–63.

[3] Ronco G, Dillner J, Elfström M, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for preventing invasive cervical cancer: follow-up of European randomised controlled trials. Lancet. 2014; 383: 524–532.

[4] Ronco G, Arbyn M, Meijer CJLM, Snijders PJF, Cuzick J. Screen-ing for cervical cancer with primary testing for human papillo-mavirus. S1. In Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Törnberg S, von Karsa L (eds.) European guidelines for quality assurance in cervical cancer screening (pp. 1–68). 2nd edn. Supplements. Luxembourg: Office for Official Publications of the European Union. 2015.

[5] Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Hernándes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. British Medical Journal. 2018; 360: k499.

[6] Skorstengaard M, Lynge E, Suhr J, Napolitano G. Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2020; 127: 729–736.

[7] Macdonald M, Smith JHF, Tidy JA, Palmer JE. Conservative management of CIN2: national audit of British society for colposcopy and cervical pathology members’ opinion. Journal of Obstetrics and Gynaecology. 2018; 38: 388–394.

[8] Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, et al. Clinical outcomes after conservative management of cervical intraepithelial neoplasia grade 2 (CIN2) in women aged 21–39 years. Cancer Prevention Research. 2018; 11: 165–170.

[9] Kremer WW, Berkhof J, Bleeker MCG, Heideman DAM, van Trommel NE, van Baal MW, et al. Role of FAM194A/miR124–2 methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study. British Medical Journal Open. 2019; 9: e029017.

[10] Brun J, Letoffet D, Marty M, Griffier R, Ah-Kit X, Garrigue I. Factors predicting the spontaneous regression of cervical high-grade squamous intraepithelial lesions (HSIL/CIN2). Archives of Gynecology and Obstetrics. 2021; 303: 1065–1073.

[11] Louvanto K, Aro K, Nedjai B, Bützow R, Jakobsson M, Kalliala I, et al. Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia. Clinical Infectious Diseases. 2020; 70: 2582–2590.

[12] Dodd RH, Cvejic E, Bell K, Black K, Bateson D, Smith MA, et al. Active surveillance as a management option for cervical intraep-ithelial neoplasia 2: an online experimental study. Gynecologic Oncology. 2021; 161: 179–187.

[13] Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Che-ung L, Chen X, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020; 22: 100293.

[14] Ordi J, Sagasta A, Munmany M, Rodríguez-Carunchio L, Torné A, del Pino M. Usefulness of p16/ki67 immunostaining in the triage of women referred to colposcopy. Cancer Cytopathology. 2014; 122: 227–235.

[15] von Knebel Doeberitz M, Prigge E. Role of DNA methylation in HPV associated lesions. Papillomavirus Research. 2019; 7: 180–183.

[16] Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven PM, et al. Methylation markers FAM194A and miR124-2 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. International Journal of Cancer. 2021; 148: 396–405.

[17] Del Mistro A, Matteucci M, Insacco EA, Onnis G, Da Re F, Baboci L, et al. Long-term clinical outcome after treatment for high-grade cervical lesions: a retrospective monoinstitutional cohort study. BioMed Research International. 2015; 2015: 984528.

[18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−∆∆CT Method. Methods. 2001; 25: 402–408.

[19] Gillio-Tos A, Fiano V, Grasso C, Trevisan M, Gori S, Mongia A, et al. Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. PLoS ONE. 2018; 13: e0194619.